Gilead targets hep B in half a billion dollar deal with Precision BioSciences - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Gilead targets hep B in half a billion dollar deal with Precision BioSciences, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Gilead targets hep B in half a billion dollar deal with Precision BioSciences
link : Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gemma Jones

14th September 2018

Biopharma looks to genome editing platform to discover hepatitis B cure

Following its success in curing hepatitis C with therapies such as Sovaldi and Harvoni, Gilead is now enlisting a new partner in the fight against hepatitis B (HBV).

Inking a collaboration deal that would be worth half a billion dollars with genome editing specialists Precision Biosciences, Gilead is aiming to develop a cure for HBV, which is proving more difficult to eliminate than hep C.

Continue reading....

Thus Article Gilead targets hep B in half a billion dollar deal with Precision BioSciences

That's an article Gilead targets hep B in half a billion dollar deal with Precision BioSciences This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Gilead targets hep B in half a billion dollar deal with Precision BioSciences with the link address https://theleknews.blogspot.com/2018/09/gilead-targets-hep-b-in-half-billion.html

Tweet

Subscribe to receive free email updates: